Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(15)00389-0 ◽

2016 ◽

Vol 15 (3) ◽

pp. 249-258 ◽

Author(s):

Emily J Henderson ◽

Stephen R Lord ◽

Matthew A Brodie ◽

Daisy M Gaunt ◽

Andrew D Lawrence ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Phase 2 ◽

Double Blind ◽

Gait Stability ◽

Double Blind Placebo ◽

Download Full-text

P1-067: AMBROXOL AS PHARMACOLOGICAL CHAPERONE TARGETING GBA1 AS A DISEASE MODIFYING TREATMENT FOR PARKINSON'S DISEASE DEMENTIA: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Alzheimer s & Dementia ◽

10.1016/j.jalz.2018.06.069 ◽

2006 ◽

Vol 14 (7S_Part_5) ◽

pp. P296-P296

Author(s):

Stephen H. Pasternak ◽

Carolina Silveira ◽

Zhonghan Li ◽

Robert Bartha ◽

Michael Borrie ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Controlled Trial ◽

Phase 2 ◽

Parkinson’S Disease Dementia ◽

Double Blind ◽

Pharmacological Chaperone ◽

Double Blind Placebo ◽

Disease Modifying ◽

Disease Modifying Treatment

Download Full-text

Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study

Parkinsonism & Related Disorders ◽

10.1016/j.parkreldis.2018.04.025 ◽

2018 ◽

Vol 53 ◽

pp. 21-27 ◽

Author(s):

Nobutaka Hattori ◽

Atsushi Takeda ◽

Shinichi Takeda ◽

Akira Nishimura ◽

Masafumi Kato ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Multicenter Study ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Yearbook of Paediatric Endocrinology ◽

10.1530/ey.17.14.9 ◽

2020 ◽

Author(s):

Harrison SA ◽

Bashir MR ◽

Guy CD ◽

Zhou R ◽

Moylan CA ◽

...

Keyword(s):

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Alcoholic Steatohepatitis ◽

Download Full-text

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Yearbook of Paediatric Endocrinology ◽

10.1530/ey.15.15.7 ◽

2018 ◽

Author(s):

Harrison SA ◽

Rinella ME ◽

Abdelmalek MF ◽

Trotter JF ◽

Paredes AH ◽

...

Keyword(s):

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Alcoholic Steatohepatitis ◽

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736628903.793573715 ◽

2020 ◽

Author(s):

Susanne Grässel

Keyword(s):

Knee Osteoarthritis ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Receptor Ligand ◽

Double Blind Placebo ◽

Disease Phenotypes ◽

Download Full-text

Faculty Opinions recommendation of Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737065221.793569342 ◽

2020 ◽

Author(s):

Joseph Jankovic ◽

Arjun Tarakad

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8286956.8718054 ◽

2011 ◽

Author(s):

Irene Litvan ◽

Rita Simoes

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Depressive Symptoms ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8638956.9139058 ◽

2011 ◽

Author(s):

John O'Brien ◽

John-Paul Taylor

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Dementia With Lewy Bodies ◽

Controlled Trial ◽

Lewy Bodies ◽

Parkinson’S Disease Dementia ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Pingchan granule for depressive symptoms in parkinson’s disease: A randomized, double-blind, placebo-controlled trial

Journal of Integrative Medicine ◽

10.1016/j.joim.2020.12.006 ◽

2020 ◽

Author(s):

Si-chun Gu ◽

Jie Zhou ◽

Qing Ye ◽

Can-xing Yuan

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Depressive Symptoms ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(14)70209-1 ◽

2014 ◽

Vol 13 (11) ◽

pp. 1100-1107 ◽

Author(s):

David W Dodick ◽

Peter J Goadsby ◽

Stephen D Silberstein ◽

Richard B Lipton ◽

Jes Olesen ◽

...

Keyword(s):

Episodic Migraine ◽

Calcitonin Gene Related Peptide ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Related Peptide ◽

Phase 2 Trial ◽

Calcitonin Gene

Download Full-text